13F Holdings
中文EN

KNSA Kiniksa Pharmaceuticals International, plc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1730430 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY58.2%
TTM net income YoY205.1%
TTM EPS YoY193.3%
Revenue 3-yr CAGR56.1%
Net income 3-yr CAGR—

Margins

Gross margin90.2%
Operating margin13.8%
Net margin11.6%
FCF margin20.8%
EBITDA margin13.9%

Returns

ROE17.6%
ROA12.9%
ROIC (approx.)19.8%
Asset turnover1.12x

Leverage & solvency

Liabilities / assets27.8%
Debt / equity0.00x
Current ratio3.91x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.81x
Accruals ratio-10.5%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$677.56M$423.24M$270.26M$220.18M$38.54M
Cost of revenue$77.67M$60.91M$33.41M$22.89M$9.10M
Gross profit$599.89M$362.33M$236.85M$197.28M$29.44M
R&D expense$96.85M$111.62M$76.10M$65.49M$99.30M
SG&A expense$196.27M$168.01M$129.43M$97.95M$85.95M
Operating income$77.22M-$45.62M-$25.20M$9.77M-$156.64M
Pretax income$88.87M-$36.15M-$16.65M$11.03M-$156.54M
Income tax$29.86M$7.04M-$30.74M-$172.34M$1.39M
Net income$59.01M-$43.19M$14.08M$183.36M-$157.92M
EBITDA$78.78M-$43.92M-$22.86M$12.18M-$154.28M
EPS (basic)0.80-0.600.202.64-2.30
EPS (diluted)0.75-0.600.202.60-2.30
Weighted avg. shares (diluted)78.98M71.42M71.92M70.42M68.58M
Balance sheet
Cash & equivalents$165.60M$183.58M$107.95M$122.72M$122.47M
Short-term investments$248.48M$60.05M$98.42M$67.89M$59.73M
Receivables$15.59M$41.72M$21.27M$12.66M$3.98M
Inventory$54.90M$26.36M$31.12M$21.60M$3.67M
Current assets$527.18M$331.80M$276.30M$243.06M$196.45M
PP&E, net$1.94M$662,000$734,000$1.66M$2.83M
Intangibles$15.25M$16.25M$17.25M$18.25M$19.25M
Total assets$763.63M$580.55M$526.32M$459.67M$232.80M
Current liabilities$139.18M$100.62M$63.67M$47.07M$44.82M
Total liabilities$196.03M$142.12M$87.48M$63.52M$47.76M
Shareholders' equity$567.61M$438.44M$438.84M$396.15M$185.04M
Cash flow statement
Operating cash flow$137.99M$25.69M$13.30M$5.81M-$126.30M
Capital expenditure$1.57M$277,000$130,000$105,000$415,000
Free cash flow$136.42M$25.41M$13.17M$5.70M-$126.71M
Investing cash flow-$188.99M$37.67M-$29.56M-$8.08M$128.63M
Financing cash flow$33.02M$12.27M$1.50M$2.52M$5.88M
Depreciation & amortization$1.55M$1.70M$2.34M$2.40M$2.35M
Stock-based compensation$37.00M$30.69M$27.15M$25.12M$25.17M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.